An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer

[1]  J. Carles,et al.  Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. , 2020, The Lancet. Oncology.

[2]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[3]  A. Thiery-Vuillemin,et al.  Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. , 2020, European urology.

[4]  M. Parmar,et al.  Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. , 2020 .

[5]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[6]  S. Culine,et al.  Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[7]  L. Howie,et al.  Blinding and Patient-Reported Outcome Completion Rates in US Food and Drug Administration Cancer Trial Submissions, 2007-2017. , 2019, Journal of the National Cancer Institute.

[8]  J. Carles,et al.  An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA) , 2018, BJU international.

[9]  E. Plimack,et al.  Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Parmar,et al.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Carles,et al.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saad,et al.  Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[14]  M. Di Maio,et al.  Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life – An Italian survey , 2017, European journal of cancer care.

[15]  F. Saad,et al.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.

[16]  Ghada El-Kamah,et al.  Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt , 2017, Hemoglobin.

[17]  D. Cella,et al.  Analysis of the Relationship Between Patient-Reported Outcomes (Pros) and Clinical Outcomes In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients without Prior Chemotherapy. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  K. Miller,et al.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[19]  D. Cella,et al.  Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. , 2015 .

[20]  H. Scher,et al.  Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. , 2013, European journal of cancer.

[21]  E. Basch,et al.  Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[22]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[23]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[24]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[25]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[26]  L. McLeod,et al.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods , 2011, Expert review of pharmacoeconomics & outcomes research.

[27]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[28]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[29]  R. Hays,et al.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.

[30]  D Feuer,et al.  Prostate cancer: palliative care and pain relief. , 2007, British medical bulletin.

[31]  M. Fishman,et al.  Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer , 2007, Quality of Life Research.

[32]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[33]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[34]  David Cella,et al.  Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI) , 2003, Health and quality of life outcomes.

[35]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[36]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[37]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Melzack.  The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.

[39]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[40]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.